A Brief Introduction and Evaluation of Typical mRNA Vaccine, Inactivated Vaccine, Vectored Vaccine, Sub-unit Vaccine for COVID Protection
- 10.2991/assehr.k.220504.052How to use a DOI?
- COVID-19; vaccine evaluation; mRNA vaccine; inactivated vaccine; vectored vaccine; sub-unit vaccine
Standing on the shoulders of giants, based on the achievements of previous researchers, scientists and vaccine developers started the most rapid vaccine development process ever since. The central topic of this paper is to introduce and evaluate four kinds of COVID vaccines created to deal with the epidemic situation and contribute to public health globally. The following description will mainly focus on a brief introduction of the working principle and how certain functions of immunity are achieved for four types of mainstream vaccines: mRNA vaccine, inactivated vaccine, vectored vaccine, and sub-unit vaccine. The evaluation of each type of vaccine mainly includes the following: the principle, the protection efficacy, and side effects. The data used in this paper all come from the previous analysis and research results from 2020 to 2022. In addition, this paper will also make some assumptions about future development in the field of COVID vaccine production based on scientific authentic numbers and results, combining the news of economics and policy. The paper finds that mRNA vaccines have high protective efficacy against the coronavirus, but their conservation cost is relatively expensive, needing to be reserved at a very low temperature to be efficient. Because of the low requirements for temperature, inactivated vaccines are easy to transport and restore. Because of this, their production efficacy is merely half that of live vaccines. Vectored vaccines have higher immunogenicity than inactivated vaccines and more readily available storage conditions than mRNA vaccines. The sub-unit vaccines seem to have characteristics of being efficient, safe, and easily achievable.
- © 2022 The Authors. Published by Atlantis Press SARL.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license.
Cite this article
TY - CONF AU - Kehan Jiao PY - 2022 DA - 2022/06/01 TI - A Brief Introduction and Evaluation of Typical mRNA Vaccine, Inactivated Vaccine, Vectored Vaccine, Sub-unit Vaccine for COVID Protection BT - Proceedings of the 2022 8th International Conference on Humanities and Social Science Research (ICHSSR 2022) PB - Atlantis Press SP - 279 EP - 285 SN - 2352-5398 UR - https://doi.org/10.2991/assehr.k.220504.052 DO - 10.2991/assehr.k.220504.052 ID - Jiao2022 ER -